Prof. Jae-Hyung Park and Dong-kyu Cho selected as regular members of KAST
top of page
앵커 1
Communication
The Korean Academy of Science and Technology announced on the 20th that it had elected 28 full members for the year 2023 at the '2022 2nd...
- Sep 27, 2022
The 'stem cell' challenge continues in the 'osteoarthritis' treatment market
[Medigate News Reporter Seo Min-ji] Although the number of patients with degenerative arthritis increases worldwide every year due to the...
- Apr 21, 2022
Exostemtech applied for phase 1 clinical trial IND in Korea for an exosome-based osteoarthritis trea
"EST-P-EXO1" aims to regenerate damaged cartilage tissue and suppress pain Bio-venture Exostemtech has applied for the domestic clinical...
- Jan 6, 2022
Daewoong Pharmaceutical and ExostemTech, joint development agreement for exosome treatment
Daewoong's 'DW-MSC' exosome extraction, purification and joint development of new indications Daewoong Pharmaceutical will join hands...
- Nov 19, 2021
[Jump-Up Bio] Exostemtech said, "The first clinical trial in Korea next year...He's even going to ge
[Anchor comment] Today's JumpUp Bio introduces Exostemtech, which develops stem cell exosome treatments. It aims to enter clinical trials...
- Nov 14, 2021
"The strength of Exostemtech is…World-class exosome mass production, analysis, and quality managemen
[an interview, ceo] The "platform technology developing, producing some the natural add-on to the following some eksso eksso" joyongu...
- Oct 26, 2021
Exostemtech, a "exosome treatment," attracts 10 billion won in series B investment (Korea economy)
Exostemtech, a bio-venture specializing in the development of exosome-based treatments, announced on the 26th that it has attracted 10...
- Jul 19, 2021
Exostemtech, Cancer Exosome Inhibitor Clinical Full-scale (The Bell)
Exostemtech, a bio-venture specializing in the development of exosome-based treatments, will begin clinical trials using cancer exosome...
- Jul 16, 2021
Exostemtech approved phase 1 and 2a clinical trials for combination of Kitruda and Exosome inhibitor
Exostemtech, a new drug developer, announced on the 16th that it has received approval from the Ministry of Food and Drug Safety for...
bottom of page